ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, ...
ENDRA Life Sciences Inc. (NDRA) is a healthcare medical-diagnostics company focused on improving clinical ultrasound capability. Its core technology is Thermo Acoustic Enhanced UltraSound (TAEUS®), a proprietary ultrasound approach intended to enhance how clinicians can interrogate tissue properties. The company’s imaging premise is based on emitting sound waves and analyzing ...ENDRA Life Sciences Inc. (NDRA) is a healthcare medical-diagnostics company focused on improving clinical ultrasound capability. Its core technology is Thermo Acoustic Enhanced UltraSound (TAEUS®), a proprietary ultrasound approach intended to enhance how clinicians can interrogate tissue properties. The company’s imaging premise is based on emitting sound waves and analyzing echo information related to internal body components (such as tissues, organs, and blood), with TAEUS® specifically positioned to support more informative measurements than conventional ultrasound in targeted use cases.
A key commercial emphasis highlighted for ENDRA is liver disease. ENDRA states that it is focused on early detection of liver disease, and it offers TAEUS® as a way to measure fat in the liver. This is important because hepatic fat measurement can be relevant in clinical assessment pathways for conditions such as nonalcoholic fatty liver disease. In addition to liver-focused imaging, the company describes applications that include temperature monitoring during thermoablative surgical procedures, vascular imaging, and assessment of tissue perfusion—suggesting that its platform concept is broader than a single diagnostic endpoint.
From a product and commercialization perspective, ENDRA also references offering/using other imaging modalities alongside enhanced ultrasound (e.g., computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound) to help clinicians visualize internal anatomy and support treatment guidance and diagnosis of conditions such as fractures, cancers, heart disease indicators, or internal bleeding. While the detailed commercial packaging varies by indication and region, ENDRA’s technology orientation is consistent: improve the diagnostic and procedural information available to healthcare providers using advanced ultrasound.
Regulatory and market progress is represented by the mention that TAEUS® is CE-marked for sale in Europe. This implies that the company is engaged in bringing the technology to market in at least some jurisdictions beyond the U.S., aligning with the company’s ongoing development and adoption efforts.
Operationally, ENDRA is a small public company. Publicly available datasets cited alongside the overview indicate approximately 9 full-time employees (and up to low-teens total employees including part-time roles), placing it in the 0–100 employee range. Leadership is provided by Alexander Y. Tokman, who serves as CEO (and has long association with the company through board and leadership roles).
Financially, the provided valuation and operating metrics suggest a development-stage or early commercialization profile, with negative profitability measures (e.g., negative return on assets/equity and negative free cash flow in the snapshot provided). In such contexts, cost control, continued research and product validation, regulatory/clinical work, and commercialization execution typically drive spending priorities (such as technology refinement, clinical evidence generation, and expansion of sales/partners). The company also indicates collaboration activity, including a research collaboration agreement with General Electric Company, which can support technology development, validation, and potential dissemination through industry relationships.
Overall, ENDRA’s “wishes” and strategic direction can be inferred from its focus areas: broaden healthcare access to better ultrasound-based diagnostic information, establish and expand clinical and regulatory acceptance for TAEUS®, and continue scaling adoption—particularly in liver-disease screening/assessment where early detection and improved measurement are central goals.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-7.0M
+38.9%
+112.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-5.2M
+29.9%
+15.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
21.8%
-26.0%
-73.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.29x
-77.3%
+1005.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
